
Sign up to save your podcasts
Or


Send us Fan Mail
The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. In addition to other pressing topics, they talk with Victoria and Paula about the national study they are about to launch, entitled STOP-HER2. It is a study to answer a burning question - is it possible for some HER2+ MBC patients, who are currently NED and have been on anti-HER2 therapy for at least 3 years, to discontinue their treatments entirely and not relapse? While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.
We’re so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you’d like us to cover? Email us at [email protected]. And don’t forget to follow us on our socials @ourmbclife.
Remember you are not alone.
By SHARE Cancer Support5
5858 ratings
Send us Fan Mail
The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. In addition to other pressing topics, they talk with Victoria and Paula about the national study they are about to launch, entitled STOP-HER2. It is a study to answer a burning question - is it possible for some HER2+ MBC patients, who are currently NED and have been on anti-HER2 therapy for at least 3 years, to discontinue their treatments entirely and not relapse? While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.
We’re so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you’d like us to cover? Email us at [email protected]. And don’t forget to follow us on our socials @ourmbclife.
Remember you are not alone.

38,856 Listeners

9,622 Listeners

65 Listeners

111,948 Listeners

56,508 Listeners

12,633 Listeners

10,446 Listeners

3,192 Listeners